Clinical Study of UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA
Key facts
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 1 Sept 2021
- Ended
- 31 Oct 2025
- Type of study
- Interventional
- Treatments tested
- UC-MSC
- Record updated
- 30 September 2026
Who can take part
- Age
- 1 year to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- 1 Age < 18 years old, gender is not limited; 2 Diagnosis of hepatitis related aplastic anemia according to the criteria for hepatitis related aplastic anemia
- The patient has a history of acute prehepatitis, and the course of hepatitis is generally less than 6 months. The main clinical manifestations are fever, jaundice, anemia, bleeding, generally no liver enlargement
- Routine blood test: pancytopenia, HGB < 100 g/L; Absolute neutrophil count < 1.5×109/L; PLT < 100×109/L (PLT reduction must be included in case of two-series reduction). Serum aminotransferase levels were elevated at least 200 U/L and hepatitis autoantibodies were negative
- Bone marrow aspiration and biopsy confirmed aplastic anemia
- Jaundice caused by other reasons and other pancytopenia diseases (such as congenital AA, clonal diseases and autoimmune diseases, etc.) are excluded; 3 No hematopoietic stem cell transplantation (HSCT); 4 The guardian and the subject will participate voluntarily and sign the informed consent
Who cannot take part
- 1 Patients will not be enrolled in this study if they meet any of the following conditions: 2. Patients with a history of hematopoietic stem cell transplantation; HIV infection or carrier in the past or at the time of screening; Positive for syphilis; 4. The subject had developed malignant solid tumors of any organ system within 5 years prior to screening; 5. Participated in other clinical trials within 3 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the effectiveness of umbilical cord mesenchymal stem cells combined with standard immunosuppressive therapy in children with HAAA, and to provide a new therapeutic idea for children with HAAA.
Read full original descriptionShow less
Whether UC-MSC combined with immunosuppressants can improve outcomes in children with HAAA.
Whether UC-MSC is safe in the treatment of children with HAAA.
Participants will:
1 Age < 18 years old, gender is not limited; 2 Diagnosis of hepatitis related aplastic anemia according to the criteria for hepatitis related aplastic anemia;
1. The patient has a history of acute prehepatitis, and the course of hepatitis is generally less than 6 months. The main clinical manifestations are fever, jaundice, anemia, bleeding, generally no liver enlargement. 2. Routine blood test: pancytopenia, HGB < 100 g/L; Absolute neutrophil count < 1.5×109/L; PLT < 100×109/L (PLT reduction must be included in case of two-series reduction). Serum aminotransferase levels were elevated at least 200 U/L and hepatitis autoantibodies were negative. 3. Bone marrow aspiration and biopsy confirmed aplastic anemia. 4. Jaundice caused by other reasons and other pancytopenia diseases (such as congenital AA, clonal diseases and autoimmune diseases, etc.) are excluded.
3 No hematopoietic stem cell transplantation (HSCT); 4 The guardian and the subject will participate voluntarily and sign the informed consent;
The group in the trial
- UC-MSC + IST groupTreatment being tested
UC-MSC Combined With Immunosuppressive Agents in the Treatment of Pediatric HAAA
Treatment: UC-MSC
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Immunosuppressive Agents in the Treatment of Children With Hepatitis Associated Aplastic Anemia
- Record updated
- 30 September 2026